<DOC>
	<DOCNO>NCT00540891</DOCNO>
	<brief_summary>Primary : Evaluate safety onset symptom relief use acute I-PSS form ( 7 day form ) . Determine onset urinary peak flow improvement 7 day Secondary : Determine improvement Bother Score 7 &amp; 28 day ; improvement sexual function 28 day ; assess one-month efficacy safety</brief_summary>
	<brief_title>The Efficacy , Onset Effect , Safety Alfuzosin Once Daily Treatment Lower Urinary Tract Symptoms Benign Prostatic Hyperplasia : A Randomized , Placebo-Controlled Trial Using Acute International Prostate Score</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Men age great equal 50 year history low urinary tract symptom ( LUTS ) relate BPH great equal 6 month , International Prostate Symptom Score ( IPSS ) ( 0 35 point scale ) least 13 point , maximum urinary flow rate ( Qmax ) 5 12 mL/sec ( voided volume great equal 150 mL ) , residual urine volume less equal 350 mL , bothersomeness score ( 0 6 point scale ) least 3 point . All patient undergo prostate size assessment transrectal ultrasonography ( TRUS ) do within past 12 month . Include , limit : concomitant lower urinary tract disease ; previous prostatic surgery ; history postural hypotension syncope ; concomitant use medication may alter void pattern ; clinically relevant biochemical abnormality . Patients serum prostatespecific antigen ( PSA ) &gt; 10 ng/mL exclude , elevate serum PSA 4 10 ng/mL must prostate cancer exclude satisfaction investigator . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>